Categories: Health

HUTCHMED to Announce 2025 Half-Year Financial Results

 | Source: HUTCHMED (China) Limited

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 03, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30, 2025 on Thursday, August 7, 2025 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT).

HUTCHMED management will host two webcast presentations for analysts and investors to discuss the interim results, followed by Q&A sessions. The English webcast will be held on Thursday, August 7, 2025, at 8:00 am EDT (1:00 pm BST / 8:00 pm HKT). The Chinese (Putonghua) webcast will be held at 8:30 am HKT / 1:30 am BST on Friday, August 8, 2025 (8:30 pm EDT on Thursday, August 7, 2025).

Both webcasts will be available live via the company website at www.hutch-med.com/event/. The presentation will be available to download shortly before the webcast begins. A replay will also be available on the website shortly after the event.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

CONTACTS

Investor Enquiries +852 2121 8200 / ir@hutch-med.com
Media Enquiries
FTI Consulting – +44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Alex Shaw +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
Brunswick – Zhou Yi +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
Panmure Liberum Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden +44 20 7886 2500
Cavendish Joint Broker
Geoff Nash / Nigel Birks +44 20 7220 0500
Deutsche Numis Joint Broker
Freddie Barnfield / Jeffrey Wong / Duncan Monteith +44 20 7260 1000
GlobeNews Wire

Recent Posts

Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may…

17 minutes ago

Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025

October 17, 2025 16:05 ET  | Source: Jade Biosciences Presentations to highlight JADE101’s preclinical safety…

17 minutes ago

HYUNDAI MOTOR GROUP TO CONNECT GLOBAL DIALOGUE AT APEC ECONOMIC LEADERS MEETING THROUGH INNOVATIVE MOBILITY

Hyundai Motor Group signed MoU with APEC Preparatory Office for APEC 2025 to support official…

18 minutes ago

Hop Lun Expands Global Manufacturing Capabilities With Strategic Acquisitions in Morocco

New plants will further diversify Hop Lun's global supply chain Upon closing, the company will…

2 hours ago

Tottenhams Small Business Scene Doubles as Major Events Transform the Area, GoDaddy Research Reveals

Friday 17 October, 2025 The concentration of small businesses in Tottenham has surged in four…

4 hours ago

HKTB Announces "Sun Hung Kai Properties Hong Kong Cyclothon" To Be Held on 30 November | Registration Now Open For 6,000 Cyclists

Hong Kong The Sun Hung Kai Properties Hong Kong Cyclothon, organised by the Hong Kong…

4 hours ago